India is facing a growing cancer burden at a time when expectations from the health system are also rising. While early detection, generic chemotherapy, and standard radiation therapy have improved outcomes for many patients, advanced cancers and relapsed disease continue to pose major challenges. In this context, CAR-T cell therapy – often described as a ‘living drug’ – has emerged globally as one of the most significant breakthroughs in cancer treatment in recent decades.
CAR-T therapy uses a patient’s own immune cells that are genetically modified to recognise and attack cancer cells. In certain blood cancers, it has produced durable remissions where conventional therapies had failed. The scientific promise is no longer in question. What remains uncertain, particularly for India, is whether its health system and policy architecture are equipped to translate this innovation into meaningful public health impact. This question matters now because India stands at an inflection point. Decisions taken today will determine whether CAR-T cell therapy becomes a niche, high-cost intervention, or a strategically integrated component of future cancer care – testing India’s capacity to govern, finance, and deploy advanced biomedical technologies at scale.
Understanding the Promise Without the Hype
The appeal of CAR-T therapy lies not only in its clinical outcomes but also in what it represents for precision medicine. Unlike conventional drugs, CAR-T cells are personalised, adaptable, and capable of long-term persistence in the body. For patients with limited treatment options, this can mean prolonged survival and, in some cases, functional cures.
At the same time, CAR-T is not a universal solution. It is complex to deliver, associated with serious side effects, and currently effective in a limited set of cancers. Recognising these constraints is essential to ground expectations and situate CAR-T within the broader oncology landscape, rather than to frame it as a replacement for existing cancer therapies. The real opportunity for India is to engage with CAR-T as a platform technology -- one that can catalyse innovation in cell and gene therapies, strengthen translational research, and build advanced manufacturing capabilities.
Where India Stands Today
India’s engagement with CAR-T cell therapy is still at an early stage. Access remains limited to a small number of centres with specialised infrastructure, trained clinical teams, and experience in handling advanced cellular products. The cost of imported CAR-T therapies has placed them well beyond the reach of most patients, reinforcing longstanding concerns around affordability and equity in access to cutting-edge cancer care.
Encouragingly, indigenous efforts to develop CAR-T therapies have begun to emerge, driven by academic institutions, start-ups, and publicly supported research initiatives. These developments signal growing scientific capability and a willingness to invest in domestic innovation. However, without a coordinated national framework, such initiatives risk remaining fragmented and slow to scale.
Why the Current System Struggles
From a health-system perspective, the integration of CAR-T therapy poses structural challenges within India’s existing public health architecture. Current public insurance schemes and tertiary-care delivery models were designed around conventional oncology interventions and are not readily configured to absorb highly personalised, high-intensity therapies such as CAR-T. As a result, pathways for financing, referral, and continuity of care remain unclear even where clinical capacity exists.
Similarly, while national cancer control programmes have prioritised early detection, access to essential treatments, and population-level impact, institutional pathways for incorporating advanced cell and gene therapies that require intensive follow-up and specialised infrastructure remain underdeveloped.
At the regulatory health system interface, progress has been made in adapting oversight mechanisms for novel biological products. However, alignment across regulators, clinical institutions, and public health payers remains uneven, shaping how – and whether – such therapies move beyond isolated centres into the broader cancer care ecosystem
Together, these factors underscore that India’s challenge is not a lack of scientific potential, but the absence of an integrated pathway that connects innovation, regulation, financing, and delivery within the broader cancer care ecosystem.
Closing the Gaps: Policy Priorities for Integrating CAR-T
The central challenge facing CAR-T cell therapy in India is not scientific feasibility, but system readiness.
Financing is the most immediate constraint. CAR-T therapy involves high upfront costs, even when developed domestically and existing public insurance schemes are not designed to accommodate such therapies. Targeted pilot financing mechanisms within public insurance programmes – linked to outcome-based evaluation – would allow policymakers to assess value while limiting fiscal exposure.
Infrastructure constraints follow closely. CAR-T delivery requires specialised laboratories, cold-chain logistics, intensive care facilities, and multidisciplinary clinical teams, capabilities currently concentrated in a handful of urban centres. Strategic public–private partnerships and shared infrastructure models could reduce duplication, expand access, and support domestic manufacturing capacity.
Workforce preparedness is equally critical. Delivering advanced immunotherapies demands specialised training for clinicians, nurses, laboratory personnel, and regulatory professionals. National training and accreditation programmes would be essential to enable safe delivery and sustainable scale-up.
Evidence generation and follow-up systems remain underdeveloped. CAR-T therapies require long-term monitoring to assess safety, durability, and real-world effectiveness. Establishing a national registry for CAR-T and related therapies would strengthen evidence generation and support regulatory and future policy decisions.
Underlying all these gaps is fragmented coordination across ministries, regulators, funders, and health systems. A coherent national strategy for cell and gene therapies – aligned across health, science, and industrial policy – would provide long-term direction and reduce institutional fragmentation.
What is at Stake if India Delays
If these gaps are not addressed, CAR-T cell therapy risks becoming another example of technological progress that fails to translate into broad societal benefit. Delayed action could lock India into dependence on high-cost imports, limit domestic innovation, and widen disparities in access to care. Conversely, early and strategic policy engagement offers India the chance to shape a model suited to its own health system realities – one that balances innovation with affordability, and excellence with equity. The stakes extend beyond CAR-T itself, influencing how India approaches future cell and gene therapies.
Looking beyond Technology
CAR-T cell immunotherapy presents India with more than a technological challenge; it offers a policy test. The question is not whether science will continue to advance, but whether governance systems can keep pace. Handled thoughtfully, CAR-T can become a catalyst for strengthening India’s translational research, manufacturing capability, and cancer care infrastructure. Mishandled, it risks reinforcing existing inequities and missed opportunities.
The choices made now will shape not only the future of CAR-T therapy in India, but also the country’s broader approach to high-impact biomedical innovation. The road ahead demands deliberate policy leadership – guided by public interest as much as by scientific possibility.
